Stock MRUS MERUS N.V.
Add to a list
To use this feature you must be a member
Log inSign up

News Merus N.V.

Equities

MRUS

NL0011606264

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-24 pm EDT 		5-day change 1st Jan Change
41.97 USD +2.99% Intraday chart for Merus N.V. +2.24% +52.62%
Apr. 19 Gilead Sciences Likely to Record IPR&D Hit on Q1 Non-GAAP Earnings, Oppenheimer Says MT
Mar. 28 Truist Securities Initiates Coverage on Merus With Buy Rating, $69 Price Target MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Merus Announces Abstracts Accepted for Presentation at the 2024 ASCO Annual Meeting
GL
Gilead Sciences Likely to Record IPR&D Hit on Q1 Non-GAAP Earnings, Oppenheimer Says
MT
Merus Presents Preclinical Data Demonstrating Efficacy of Zeno in Cancer Models with High NRG1 Expression at the AACR Annual Meeting 2024
GL
Merus Presents Preclinical Data Demonstrating Efficacy of Zeno in Cancer Models with High NRG1 Expression at the AACR Annual Meeting 2024
AQ
Merus to Participate in a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
GL
Merus to Participate in a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
AQ
Truist Securities Initiates Coverage on Merus With Buy Rating, $69 Price Target
MT
Needham Raises Price Target on Merus to $66 From $65, Maintains Buy Rating
MT
Gilead Sciences, Merus Collaborate to Discover New Potential Cancer Therapies
MT
Gilead, Merus to Collaborate on Trispecific Antibody Research
DJ
Gilead Sciences, Inc. and Merus N.V. Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers
CI
Merus Announces Publication of an Abstract for Presentation at the AACR Annual Meeting 2024: Zeno is effective in cancer models with high NRG1 expression
GL
Merus Announces Publication of an Abstract for Presentation at the AACR Annual Meeting 2024: Zeno is effective in cancer models with high NRG1 expression
AQ
Merus N.V. announced that it has received $25.000035 million in funding from Gilead Sciences, Inc.
CI
Needham Raises Price Target on Merus to $65 From $42, Keeps Buy Rating
MT
Merus to Participate in a Fireside Chat at the Leerink Partners Global Biopharma Conference
GL
Merus to Participate in a Fireside Chat at the Leerink Partners Global Biopharma Conference
AQ
Merus Full-Year 2023 Net Loss Widens, Revenue Increases
MT
Earnings Flash (MRUS) MERUS N.V. Posts 2023 Revenue $43.95M
MT
Merus Announces Financial Results for the Fourth Quarter and Full Year 2023 and Provides Business Update
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MRUS Stock
  4. News Merus N.V.